MedShape Sells ExoShape® ACL Product Line to CONMED Corporation

Posted On July 6, 2017 By OrthoSpineNews In Extremities, Top Stories /

ATLANTA, July 5, 2017 /PRNewswire/ — MedShape, Inc., the industry leader in orthopaedic devices using advanced functional materials, announced today that it has reached a definitive agreement with CONMED Corporation (Nasdaq:CNMD) for CONMED to acquire the ExoShape® ACL Fixation System. The acquisition, which closed July 3, 2017, includes both the ExoShape FEMORAL and TIBIAL Soft Tissue Fasteners, used to fixate soft tissue grafts in anterior cruciate ligament (ACL) reconstruction surgery.

“The ExoShape System has represented a valuable portion of MedShape’s business since 2011, and this acquisition further demonstrates the success of the development and commercialization efforts invested in the product,” said Kurt Jacobus, MedShape’s CEO. “While we will certainly miss serving our patients, doctors and distributors with this product line, we look forward to focusing our efforts towards growing our core foot and ankle business with new investments.”

The ExoShape ACL Fixation System represents a breakthrough in soft tissue fixation, as it was the first all-PEEK system to offer a non-rotational deployment and interference fixation approach for ACL reconstruction. Manufactured out of shape memory PEEK Altera®, the ExoShape fasteners are delivered in a low-profile shape for easy insertion and then fully expanded upon instantaneous deployment to effectively compress and secure the soft tissue graft inside the bone tunnel.

About CONMED Corporation

CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. CONMED has a direct selling presence in 17 countries, and international sales constitute approximately 50% of the Company’s total sales. Headquartered in Utica, New York, the Company employs approximately 3,300 people. For more information, visit www.conmed.com.

About MedShape, Inc.

MedShape, Inc. is a privately held medical device company working to develop and commercialize a portfolio of surgical solutions for foot and ankle and trauma surgeons that use its patented advanced material technologies. For more information, visit: www.medshape.com.

Media Contact:
Jenn Pratt
Carabiner Communications
404.655.2273
jpratt@carabinerpr.com

MedShape, Inc. Contact:
Kathryn Smith, Ph.D.
678.235.3304
Kathryn.smith@medshape.com

CONMED Corporation Contact:
Luke Pomilio
Chief Financial Officer
315.624.3202
LukePomilio@conmed.com

SOURCE MedShape, Inc.

Stryker Unveils Hoffmann LRF Hexapod With Pre And Post-Operative Planning Tool For Deformity Correction & Limb Reconstruction Procedures

Posted On June 29, 2017 By OrthoSpineNews In Extremities /

MAHWAH, N.J., June 29, 2017 /PRNewswire/ — Stryker’s Foot and Ankle business unit today announced the upcoming launch of its new Hoffmann LRF Hexapod hardware and online application, featuring an advanced measurement tool that uses a mathematical algorithm to calculate solutions to correct the deformity. Hoffmann LRF Hexapod is being demonstrated during the American Orthopaedic Foot & Ankle Society (AOFAS) annual meeting from July 12-14 in Seattle.

“Stryker’s Hoffmann LRF Hexapod and its innovative software is a step forward for surgeons and patients involved with complex deformity correction and limb reconstruction procedures. The product is the first-of-its-kind, offering top, as opposed to side, actuating struts, making it easier for patients to reach and manage the hardware,” said John Sontich, MD, Chief of Orthopaedic Trauma at University Hospitals Cleveland Medical Center and past president of the Limb Lengthening and Reconstruction Society. “I am looking forward to using these new technologies to help enhance the patient experience from the first consultation to the end of someone’s treatment.”

Unlike traditional pre-planning, surgeons can upload a patient’s x-rays into the software, which then calculates a treatment solution based on manual inputs by the surgeon, creating a patient-specific plan for strut adjustments. The Hoffmann LRF Hexapod hardware features the core components of Hoffmann LRF with additional flexibility of strut offsetting, allowing the user to relocate the struts to a more optimal position.

Based on the simplicity and reliability of the original Hoffmann Fixator, the versatile Hoffmann LRF product line is designed to match today’s biological repair and reconstruction methods.

“Our team is excited to showcase the benefits of the Hoffmann LRF platform and its intuitive software at AOFAS,” said Tom Popeck, Vice President and General Manager of Stryker’s Foot and Ankle business unit. “We believe this modern deformity correction platform helps streamline the surgical planning process and demonstrates our dedication to moving technology forward with our surgeons and patients best interest in mind.”

Other products and services that will be showcased at Stryker’s AOFAS exhibit (booth #1001) include:

VariAx 2® Fracture Plates
VariAx 2® Fracture Plates are SOMA designed for an enhanced fit. These plates are available in a variety of lengths and sizes (two to seven holes), offered in slim and broad options, and indicated for the foot, ankle, hand and wrist.
ToeTac
ToeTac is a sterile-packed PEEK cannulated hammertoe fixation product that does not require cold chain storage and includes cup and cone reamers allowing for simple K-wire fixation of adjacent joints.
M.O.R.E. (Mobile Operating Room Experience)
M.O.R.E. is designed to educate the entire surgical care team on Stryker’s products and surgical techniques, providing a hands-on experience in their local community.

For more information about Hoffmann LRF product line, please visit https://footankle.stryker.com/en/products. Surgeons may request or access their account by visiting https://fixmyleg.stryker.com.

About Stryker
Stryker is one of the world’s leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world.

This document is only approved for use in the USA.
Content ID: H-BL-10, 06-2017

SOURCE Stryker Orthopaedics

Conventus Orthopaedics Strengthens Company Leadership

Posted On June 26, 2017 By OrthoSpineNews In Extremities /

MINNEAPOLIS, June 26, 2017 /PRNewswire/ — Conventus Orthopaedics, Inc., a medical device company dedicated to revolutionizing extremity fracture treatment, today announced that Matthew Jewett will join the company on June 26, 2017 as its new Chief Executive Officer. Jewett, an experienced medical device industry executive known for building high-performing teams, developing new markets, and driving revenue growth, will also serve on the company’s Board of Directors.

“Matt’s strategic acumen and proven track record of leadership within orthopaedics made him the ideal choice to lead Conventus,” said Scott Flora, Chairman of the Board for Conventus. “We are pleased to have Matt join our company as we work to establish the Cage™ technology as the standard-of-care for the treatment of extremity fractures.”

Jewett joins Conventus following a successful career at Johnson & Johnson where he held multiple executive leadership positions within the DePuy Synthes business. “I’m excited for the opportunity to lead Conventus, a company with a truly innovative technology for the treatment of extremity fractures,” Jewett said. “The Cage technology has the potential to both positively impact patient treatment outcomes as well as reduce the cost of care for extremity fracture treatment.”

Andrew ElBardissi, MD, a surgeon and an investor at Deerfield Management, the largest investor in the company, was also appointed to Conventus’ Board of Directors. “We are thrilled to welcome Matt as a preeminent leader in orthopaedics and we are excited to help bring an innovative platform technology to market that will transform the treatment of patients with extremity fractures,” said Dr. ElBardissi. “Our recent investment, coupled with Matt’s appointment illustrates our commitment to build Conventus into an innovative and leading orthopaedic company.”

About Conventus Orthopaedics, Inc.

Conventus Orthopaedics, Inc. is an early-stage company focused on delivering a new standard of care for orthopedic fracture treatment, including complex and fragility fractures where there is a significant unmet need and a lack of treatment options. Their proprietary Cage™ technology aims to improve patient outcomes, enhance the surgeon experience, and deliver economic value to stakeholders within this market segment.

SOURCE Conventus Orthopaedics, Inc.

$DePuy Synthes launches single use instrument kits for wrist fractures$

DePuy Synthes launches single use instrument kits for wrist fractures

Posted On June 23, 2017 By OrthoSpineNews In Extremities /

23 June, 2017

DePuy Synthes, part of the Johnson & Johnson Family of Companies, has introduced the Distal Radius Sterile Kit, a pre-sterilised, single-use kit of instruments and implants to treat wrist fractures.

The announcement was made to the health care community during the combined congress of the Federation of European Societies for Surgery of the Hand and European Federation of Societies.

The kits provide customers with the company’s market-leading plate and screw implants as well as pre-sterilised, single-use instrumentation that helps improve operating room efficiency, streamlines the procedure and eliminates sterilisation costs. In fact, the Distal Radius Sterile Kit was designed to eliminate more than 60% of steps associated with processing reusable sets.¹

Wrist fractures are one of the most common fracture types, accounting for up to 18% in the elderly, and rates of surgery to fix them are increasing.² With this rise in demand for surgical procedures, surgeons and providers want a solution that enables high-quality treatment for patients while improving efficiency, reducing costs and minimising delays associated with instrumentation and sterilisation. One study demonstrated that surgical delays as brief as 10 minutes may cost a hospital more than $130,000 per year.³

READ THE REST HERE

‘Cool’ New Knee Procedure Eases Arthritis Pain Without Surgery

Posted On June 15, 2017 By OrthoSpineNews In Extremities, Sports Medicine /

by LAUREN DUNN and FELIX GUSSONE, MD

A new, non-invasive knee procedure could bring some relief for patients suffering from debilitating chronic pain, for whom surgery is not an option.

The treatment, recently approved by the Food and Drug Administration, is called “cooled radio frequency ablation” and is a less drastic option for people with moderate to severe osteoarthritis pain who are not ready to have knee replacement surgery, or who have health conditions that don’t make them a good candidate for surgery.

Marketed as “Coolief”, the procedure uses radio frequency to target and mute the nerves responsible for sending pain signals from the arthritic knee to the brain. Coolief doesn’t repair arthritis in the knee, but eases the pain, helping patients go back to activities without discomfort and fewer medications.

“What we’re changing is the wiring of the knee — so we’re taking away the pain signal and interrupting it,” Dr. Amin Sandeep, a pain specialist at Rush University Medical Center in Chicago who performs the procedure, told NBC News.

One 2016 study compared Coolief to popular cortisone injections, with patients reporting greater, longer-lasting pain relief with the new treatment than injections. Coolief reduces pain for about to 6 to 12 months, depending on how fast the nerves in the knee regenerate.

READ THE REST HERE

01-211-0001_OL1000_single_coil_size1_on_lady_lowres_0.png

DJO Global, Inc. Announces Clinical Trial for a New Indication for CMF OL1000™ Bone Growth Stimulators

Posted On June 14, 2017 By OrthoSpineNews In Extremities, Top Stories /

June 13, 2017

SAN DIEGO–(BUSINESS WIRE)–DJO Global, Inc. (“DJO Global” or the “Company”), a leading global provider of medical technologies designed to get and keep people moving, announces the onset of a clinical trial for a new indication of the CMF OL1000 Bone Growth Stimulator.

Combined Magnetic Field (CMF) devices have been on the market since the early 1990s, providing medical professionals with a tool for the noninvasive treatment of an established non-union fracture acquired secondary to trauma, excluding all vertebrae and flat bones. Due to the type of signal technology, CMF devices are prescribed for a treatment time of 30-minutes per day. These battery-powered, FDA-approved medical devices can be used in conjunction with non-magnetic internal or external fixation, over a cast or brace.

DJO Global, through its subsidiary, Encore Medical L.P., initiated the application for an Investigational Device Exemption (IDE) Study with the U.S. Food and Drug Administration (FDA) for a new indication of the CMF technology into the fresh fracture market. The prospective, randomized, double-blinded, controlled, multi-center clinical study will evaluate the use of the CMF OL1000 as a noninvasive adjunctive treatment for closed, unstable ankle fractures that require surgical treatment for stabilization. The FDA-approved study initiated enrollment in January of this year.

For more information on this study, please visit: https://www.clinicaltrials.gov/ct2/show/NCT02688855?term=NCT02688855&rank=1.

For more information on the CMF product portfolio, please visit: http://www.djoglobal.com/our-brands/cmf.

About DJO Global

DJO Global is a leading global provider of medical technologies designed to get and keep people moving. The Company’s products address the continuum of patient care from injury prevention to rehabilitation after surgery, injury or from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopaedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopaedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO Global’s products are marketed under a portfolio of brands including Aircast®, Chattanooga, CMF™, Compex®, DonJoy®, ProCare®, DJO® Surgical, Dr. Comfort® and ExosTM. For additional information on the Company, please visit www.DJOglobal.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements relate to, among other things, the Company’s expectations regarding the success of the announced clinical trial which are subject to a number of risks, uncertainties and assumptions, many of which are beyond the Company’s ability to control or predict. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. The important factors that could cause the announced clinical trial to not be successful or to differ significantly from the Company’s expectations which are expressed or implied by such forward-looking statements include, but are not limited to the successful execution of the Company’s clinical trial, including complying with regulations applicable to such clinical trials; the failure to receive positive clinical results for this product, and even if we receive positive clinical results, the failure to receive the necessary clearance or approvals from the applicable government regulators to market and sell our products for the desired indications; and the uncertainty of acceptance by healthcare providers of the use of the Company’s product for the requested new indications. These and other risk factors related to DJO Global are detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on March 15, 2017. Many of the factors that will determine the outcome of the subject matter of this press release are beyond the Company’s ability to control or predict.

Contacts

DJO Media Contact:
Brittany Knudson
Marketing Director
760.681.7785
Brittany.Knudson@djoglobal.com
or
DJO Investor Contact:
David Smith
SVP and Treasurer
760.734.3075
ir@djoglobal.com

Extremity Reconstruction Market : By Product Type, Market, Players and Regions-Forecast to 2025

Posted On June 14, 2017 By OrthoSpineNews In Extremities /

Press release from: TMR Research – 06-14-2017

The global market for extremity reconstruction is expected to witness a high level of growth in the next few years. The rising number of cases of abnormalities and injuries in the lower and upper extremity of the human body is one of the vital factors estimated to encourage the growth of the global market in the coming years. In addition, several advancements in the healthcare infrastructure are anticipated to accelerate the development of the market in the near future. The implant devices for different parts of the human body comprises the extremity reconstruction market in the coming years.

A tremendous rise in the geriatric population and the rising incidences of obesity and diabetes are some of the major factors that are estimated to fuel the development of the global extremity reconstruction market in the near future. Moreover, the increasing cases of osteoarthritis and rheumatoid are likely to accelerate the growth of the market in the coming years. The rising awareness regarding the benefits of small joint reconstruction implants among patients is predicted to encourage the growth of the global extremity reconstruction market in the next few years.
Request Sample Copy of the Report @ www.tmrresearch.com/sample/sample?flag=B&rep_id=1175

Technological advancements and the availability of required infrastructure are projected to augment extremity reconstruction market in North America market in the next few years. The leading players operating in the extremity reconstruction market across the globe are emphasizing on introducing innovative implants in order to attract a large number of consumers and attain a leading position in the market. Additionally, the rising level of competition is predicted to expand the product portfolio and benefit the patients in the coming years.

Global Extremity Reconstruction Market: Overview

The increasing incidence of injuries, abnormalities, and congenital defects in the upper or lower extremity of human body has fueled the demand for reconstructive surgical procedures. Implant devices for the shoulder, wrist, ankle joints, digits, elbow, and foot are part of the extremity reconstruction market.

Request TOC of the Report @ www.tmrresearch.com/sample/sample?flag=T&rep_id=1175

The primary driver of the global extremity reconstruction market is the large pool of geriatric population. According to the Centers of Disease Control and Prevention, with a rise in the geriatric population in the U.S., by the year 2040, the number of patients affected by arthritis is expected to increase to 78 million. Since aged people are more prone to injuries, growth in geriatric population is expected to fuel the demand for reconstructive surgical procedures.

READ THE REST HERE

Oska® Wellness Announced as the Presenting Sponsor for the 4th Annual Midwest Pain Treatment Education Expo

Posted On June 13, 2017 By OrthoSpineNews In Extremities, Sports Medicine, Top Stories /

CARLSBAD, Calif., April 18, 2017 /PRNewswire/ — Oska Wellness, a technology company committed to developing cutting-edge consumer health and wellness products, is the presenting sponsor for the 4^th Annual Midwest Pain Treatment Education Expo, August 13, 2017 at the Hilton Hotel, Northbrook, Illinois.

Oska Wellness will have a booth at the Expo with top Oska executives on hand to showcase the benefits of the Oska® Pulse, a revolutionary wearable device to combat pain. The company has donated 10 Oska Pulse devices to be given away as door prizes, along with 20 additional devices to be gifted (to the first 10 people in line at 8 a.m. and again to the first 10 people at 1 p.m.).

The Midwest Pain Treatment Education Expo is produced by Gracie Bagosy-Young, a chronic pain patient advocate and president of the GG Chronic Pain Foundation, whose mission is to raise awareness of chronic pain conditions and educate the chronic pain community on non-drug options and current research.

“This is our biggest outreach event, with outstanding speakers, exhibitors and attendees from all over the country, and will be streamed on Facebook Live and Livestream all over the world,” said Bagosy-Young. “I’m thrilled that Oska Wellness has joined me as presenting sponsor for the Expo and to help spread the message about new non-drug options for managing pain.”

Oska Wellness recently unveiled the new Oska Pulse a small, portable, hands-free device that employs safe Pulsed Electromagnetic Field (PEMF) therapeutic technology, a longtime therapy used by medical practitioners to help people enjoy more active, pain-free and drug-free lives.

“We’re very excited to sponsor the Midwest Pain Treatment Education Expo and share our mission on new ways to provide non-invasive, drug free pain management solutions,” said Greg Houlgate, CEO of Oska Wellness. “Oska Pulse is a smart, safe, easy-to-use, wearable health technology product designed to help reduce muscle stiffness, temporarily relieve minor pain and increase mobility for people who have chronic pain. We will be showcasing Oska Pulse and the benefits of PEMF technology to hundreds of attendees at the Expo.”

For more information and ticket options for the Midwest Pain Education Expo, please contact Gracie Bagosy-Young at gracie@ggpainadvocacy.com.

About Oska Wellness
Oska, Inc. is committed to developing health and wellness technology-driven products that assist individuals in living a more active, pain-free lifestyle. Oska Pulse utilizes patented eTec Pulse Technology that specifically optimizes Pulsed Electromagnetic Field (PEMF) therapeutic technology, similar to the PEMF therapies used in many clinical applications for accelerating the body’s ability to heal itself.

The science and technology behind Oska Pulse was engineered and developed by a team of respected scientists and researchers with over 25 years of experience in engineering health and wellness technologies to treat pain. Oska Wellness, Inc. does not claim the product to diagnose, treat, cure or prevent any medical condition. The company is headquartered in Carlsbad, California and can be found online at www.oksawellness.com.

ADD COUPON CODE “ORTHOSPINECO” FOR $55.00 OFF

Spring Loaded Technology Officially Launches LevitationTM, the World’s First Compact Bionic Knee Brace, with support from Government of Canada

Posted On June 9, 2017 By OrthoSpineNews In Extremities, Sports Medicine, Top Stories /

HALIFAX, NS – June 9, 2017 – Spring Loaded Technology announces the official launch of its Levitation^TM bionic knee brace for consumer sales across North America, and is now welcoming commercial partnerships with clinics, distributors, and brace retailers across Canada. The product launch takes place as the Government of Canada announces a $2.46-million investment through the Atlantic Canada Opportunities Agency’s Atlantic Innovation Fund (AIF).

Spring Loaded Technology CEO Chris Cowper-Smith describes the announcement as “The next chapter in our journey to change and improve lives in a big way.” COO Dawn Umlah added, “With the support of ACOA, combined with our research and development efforts and leading-edge product development, it’s a game changer. We’re proud to be able to put the world’s first and only compact, bionic knee brace into the hands of consumers on a large scale.”

As the world’s first bionic knee brace, Levitation™ uniquely enhances knee strength, mobility, and endurance by storing energy as the leg bends and then returning that energy as the leg straightens. Current users range from performance athletes, to manual laborers, to people with osteoarthritis. Levitation has proven useful for most knee injuries and conditions.

“The team at Spring Loaded Technology is transforming the versatility of assistive devices,” says

Darren Fisher, Member of Parliament for Dartmouth-Cole Harbour. “They represent a broader

life sciences community working on research that brings solutions to the marketplace. Targeted

investments such as these are helping us grow beyond our borders in line with our Atlantic

Growth Strategy.”

After successfully securing USD $208,000 through an Indiegogo crowdfunding campaign, delivering a $1-million contract for the Canadian forces, and fulfilling hundreds of consumer pre-orders, the Nova Scotia company is entering what they call real-time production. With bolstered manufacturing capacity, product improvements, and increased demand, Spring Loaded Technology is positioned to deliver Levitation across North America, to help people do more of what they love.

To learn more about Levitation™ and Spring Loaded Technology, or to inquire about partnership opportunities, visit www. springloadedtechnology.com.

About Spring Loaded Technology

Spring Loaded Technology is an award-winning company based in Halifax, Nova Scotia, which has designed an entirely new knee bracing technology to enhance the strength and power of the leg muscles. By increasing leg strength, their technology can be used in a wide range of applications including: mobility assistance, fatigue reduction, injury prevention/rehabilitation, and performance enhancement. The company was founded in 2012.

Media Contacts:

Kaleigh DeHart

Uproar PR for Spring Loaded Technology

Office: 321.236.0102

Email: kdehart@uproarpr.com

Alex Smith

Director of Communications and Outreach, Atlantic Canada Opportunities Agency

Cell: (902) 830-3839
Office: (902) 426-9417
E-mail: alex.smith@canada.ca

Oska® Wellness Honored with MedTech Breakthrough Award

Posted On June 7, 2017 By OrthoSpineNews In Extremities, Sports Medicine, Top Stories /

CARLSBAD, CA, June 7, 2017 – Oska Wellness, a technology company committed to developing consumer health and wellness products, announced that its Oska Pulse has been selected as the “Best IoT Healthcare Wearable Device” award winner from MedTech Breakthrough, an independent organization that recognizes the top companies, technologies and products in the global health and medical technology market.

“All of us at Oska are excited to receive this award from MedTech, who have recognized Oska’s mission to provide non-invasive, drug-free pain management solutions,” said Greg Houlgate, Oska Wellness CEO. “This is an important industry recognition for our year-old company and our flagship device, Oska Pulse. We’re very grateful.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Patient Engagement, Electronic Health Records (HER), mHealth, Medical Devices, Medical Data and many more. This year’s program attracted more than 2,000 nominations from more than 10 countries. All nominations were evaluated by an independent panel of experts within the medical and health industry, including media, analysts, and technology executives.

“We are thrilled to recognize Oska Wellness with this well-deserved industry recognition for innovation in the health and medical technology field,” said James Johnson, managing director, MedTech Breakthrough. “For the millions of Americans that suffer from chronic pain, Oska Pulse is a compelling solution and the MedTech Breakthrough Award designation is a testament to the skill, ingenuity, and vision of the Oska Wellness team.”

Oska Pulse is a safe, easy-to-use, portable and wearable health technology product designed to help reduce muscle stiffness, temporarily relieve minor pain and increase mobility for people who have acute or chronic pain.

The science and technology behind Oska Pulse was engineered and developed by a team of respected scientists and researchers with more than 25 years of experience in engineering health and wellness technologies to treat pain. Oska Wellness, Inc. does not claim the product to diagnose, treat, cure or prevent any medical condition. The company is headquartered in Carlsbad, California and can be found online at www.oksawellness.com.

About MedTech Breakthrough
The MedTech Breakthrough Awards program is devoted to honoring excellence in medical and health related technology companies, products and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough MedTech companies and products in categories including Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Genomics, Medical Data, Healthcare Cybersecurity and more. For more information visit www.MedTechBreakthrough.com

ADD COUPON CODE “ORTHOSPINECO” FOR $55.00 OFF